MedTrace Logo

NWRD06 DNA Plasmid for HCC After Radical Resection

NCT06088459 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-10-18

No results posted yet for this study

Summary

This is a dose escalation Phase 1 clinical study to evaluate the safety and immunogenicity of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after radical resection.

Conditions

Interventions

BIOLOGICAL

1mg NWRD06 administered by electroporation

DNA plasmid delivered via IM injection + electroporation using TERESA device

BIOLOGICAL

4mg NWRD06 administered by electroporation

DNA plasmid delivered via IM injection + electroporation using TERESA device

BIOLOGICAL

8mg NWRD06 administered by electroporation

DNA plasmid delivered via IM injection + electroporation using TERESA device

Sponsors & Collaborators

  • Newish Technology (Beijing) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhao Hong, Ph.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06088459 on ClinicalTrials.gov